Maze Therapeutics (MAZE) Accounts Payables (2024 - 2026)
Maze Therapeutics (MAZE) posted Accounts Payables of $4.0 million for Q1 2026, up 123.69% sequentially from $1.8 million in Q4 2025, and up 66.93% YoY from $2.4 million in Q1 2025.
Maze Therapeutics (MAZE) Accounts Payables (2024 - 2026) Analysis & Trends
Maze Therapeutics has reported Accounts Payables for 3 years, with the latest figure at $4.0 million in Q1 2026.
- Quarterly Accounts Payables rose 66.93% year-over-year to $4.0 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $4.0 million (up 66.93% YoY) and the FY2025 annual result came in at $1.8 million, down 7.48% from the prior year.
- Accounts Payables improved to $4.0 million in Q1 2026 per MAZE's latest filing, from $1.8 million in the prior quarter.
- Over five years, Accounts Payables peaked at $4.0 million in Q1 2026 and troughed at $1.8 million in Q4 2025.
- A 3-year average of $2.8 million and a median of $2.7 million in 2025 frame the typical range for Accounts Payables.
- The sharpest annual moves came in 2025 and 2026: Accounts Payables decreased 7.48% in 2025, then jumped 66.93% in 2026.
- Over 3 years, Accounts Payables stood at $1.9 million in 2024, then fell by 7.48% to $1.8 million in 2025, then jumped by 123.69% to $4.0 million in 2026.
- According to Business Quant data, Accounts Payables over the past three periods registered $4.0 million, $1.8 million, and $2.9 million for Q1 2026, Q4 2025, and Q3 2025 respectively.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Accounts Payables (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 128.13 Bn | 120.28 Bn | 2.84 Bn | 429.50 Mn |
| 2 | Regeneron Pharmaceuticals | 112.33 Bn | 104.33 Bn | 3.93 Bn | 1.16 Bn |
| 3 | Argenx Se | 53.24 Bn | 48.05 Bn | 1.41 Bn | 1.52 Bn |
| 4 | Revolution Medicines | 43.64 Bn | 43.64 Bn | - | 88.42 Mn |
| 5 | BeOne Medicines | 39.27 Bn | 34.17 Bn | 1.53 Bn | 470.30 Mn |
| 6 | MindWalk Holdings | 35.32 Bn | 35.31 Bn | 1.82 Bn | 3.05 Mn |
| 7 | Royalty Pharma | 33.72 Bn | 35.84 Bn | - | 35.57 Mn |
| 8 | Alnylam Pharmaceuticals | 30.58 Bn | 27.27 Bn | 992.69 Mn | 108.02 Mn |
| 9 | Insmed | 27.01 Bn | 25.85 Bn | 358.27 Mn | 428.93 Mn |
| 10 | Maze Therapeutics | 1.51 Bn | 1.51 Bn | - | 2.21 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 2.21 Mn |
| Mar 31, 2026 | 4.01 Mn |
| Dec 31, 2025 | 1.79 Mn |
| Sep 30, 2025 | 2.92 Mn |
| Jun 30, 2025 | 3.67 Mn |
| Mar 31, 2025 | 2.40 Mn |
| Dec 31, 2024 | 1.94 Mn |